What is Clene Inc.'s market cap?

Clene Inc. (CLNN) has a market capitalization of $69.8M and trades on NASDAQ.

Who are Clene Inc.'s competitors?

Clene Inc.'s key competitors include Biogen Inc., NextCure, Inc. Common Stock, CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Clene Inc. partner with?

Clene Inc.'s notable partners include 4Life Research LLC, Synapticure, Massachusetts General Hospital, and others.

What subsidiaries does Clene Inc. have?

Clene Inc.'s subsidiaries include dOrbital, Inc..

Where is Clene Inc. headquartered?

Clene Inc. is headquartered in United States of America and employs approximately 85 people. It has been publicly traded since 2020.

Clene Inc.

CLNN

Clene Inc. is a clinical-stage pharmaceutical company that develops novel nanotechnology-based therapeutics using a proprietary electro-crystal-chemistry platform.

Market cap

$69.77M+123%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$15.0KMiss by $35.8K EPS-$0.31Beat by $0.19

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$61.0K

EPS estimate-$0.37

Competitors

By market cap

Biogen$29.5B+56.0%

Sionna Therapeutics, Inc.$2.0B+134%

CorMedix$596.2M-33.1%

Clene Inc.$69.8M+128%

NXT

NextCure, Inc.$20.8M+40.5%

CNS Pharmaceuticals$7.4M-83.4%

CUR

Curanex Pharmaceuticals Inc Common Stock$5.2M—

Matinas BioPharma$2.1M-55.0%

By revenue growth

CorMedix+385%

Biogen+0.3%

By net margin

CorMedix45.25%+58.3pp

Biogen8.81%-6.5pp

Profile

Clene Inc. is a clinical-stage pharmaceutical company that develops novel nanotechnology-based therapeutics using a proprietary electro-crystal-chemistry platform. The company specializes in clean-surfaced nanocrystals that act as biological catalysts to address cellular energy failure and oxidative stress. Its primary focus is on treating neurodegenerative diseases, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease.

Competitive position

Clene is a pioneer in the use of catalytically-active nanocrystals for biological modulation, holding a significant patent-protected position in clean-surfaced nanotechnology.

GeographiesUnited States, Australia, Canada, Brazil

Customer segmentsPatients with neurodegenerative diseases, Health supplement consumers

Business modelR&D intensive, Licensing, Direct-to-consumer

SuppliersTransition element raw material suppliers, Specialized laboratory equipment manufacturers, Contract Research Organizations (CROs)

CustomersSpecialty health clinics, Academic research institutions, Health supplement distributors

CountryUnited States of America

Listed2020

Employees85.0

CEORobert Etherington

SectorHealthcare

IndustryBiotechnology

Websiteclene.com

FilingsSEC EDGAR

Questions, answered.

What is Clene Inc.'s market cap?: Clene Inc. (CLNN) has a market capitalization of $69.8M and trades on NASDAQ.
Who are Clene Inc.'s competitors?: Clene Inc.'s key competitors include Biogen Inc., NextCure, Inc. Common Stock, CNS Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Clene Inc. partner with?: Clene Inc.'s notable partners include 4Life Research LLC, Synapticure, Massachusetts General Hospital, and others.
What subsidiaries does Clene Inc. have?: Clene Inc.'s subsidiaries include dOrbital, Inc..
Where is Clene Inc. headquartered?: Clene Inc. is headquartered in United States of America and employs approximately 85 people. It has been publicly traded since 2020.